Literature DB >> 12417637

D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release.

Agnès Auclair1, Susanna Cotecchia, Jacques Glowinski, Jean-Pol Tassin.   

Abstract

It was found recently that locomotor and rewarding effects of psychostimulants and opiates were dramatically decreased or suppressed in mice lacking alpha1b-adrenergic receptors [alpha1b-adrenergic receptor knock-outs (alpha1bAR-KOs)] (Drouin et al., 2002). Here we show that blunted locomotor responses induced by 3 and 6 mg/kg d-amphetamine in alpha1bAR-KO mice [-84 and -74%, respectively, when compared with wild-type (WT) mice] are correlated with an absence of d-amphetamine-induced increase in extracellular dopamine (DA) levels in the nucleus accumbens of alpha1bAR-KO mice. Moreover, basal extracellular DA levels in the nucleus accumbens are lower in alpha1bAR-KO than in WT littermates (-28%; p < 0.001). In rats however, prazosin, an alpha1-adrenergic antagonist, decreases d-amphetamine-induced locomotor hyperactivity without affecting extracellular DA levels in the nucleus accumbens, a finding related to the presence of an important nonfunctional release of DA (Darracq et al., 1998). We show here that local d-amphetamine releases nonfunctional DA with the same affinity but a more than threefold lower amplitude in C57BL6/J mice than in Sprague Dawley rats. Altogether, this suggests that a trans-synaptic mechanism amplifies functional DA into nonfunctional DA release. Our data confirm the presence of a powerful coupling between noradrenergic and dopaminergic neurons through the stimulation of alpha1b-adrenergic receptors and indicate that nonfunctional DA release is critical in the interpretation of changes in extracellular DA levels. These results suggest that alpha1b-adrenergic receptors may be important therapeutic pharmacological targets not only in addiction but also in psychosis because most neuroleptics possess anti-alpha1-adrenergic properties.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417637      PMCID: PMC6758052     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Role of serotonin in cocaine effects in mice with reduced dopamine transporter function.

Authors:  Yolanda Mateo; Evgeny A Budygin; Carrie E John; Sara R Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

Review 3.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

4.  Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons.

Authors:  Lucas Salomon; Christophe Lanteri; Jacques Glowinski; Jean-Pol Tassin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

Review 5.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 6.  The role of the central noradrenergic system in behavioral inhibition.

Authors:  Eric A Stone; Yan Lin; Yasmeen Sarfraz; David Quartermain
Journal:  Brain Res Rev       Date:  2011-03-05

7.  Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission.

Authors:  Yukio Ago; Ryota Araki; Koji Yano; Naoki Hiramatsu; Toshiyuki Kawasaki; Shigeyuki Chaki; Atsuro Nakazato; Hirotaka Onoe; Hitoshi Hashimoto; Akemichi Baba; Kazuhiro Takuma; Toshio Matsuda
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

Review 8.  Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-03-11       Impact factor: 4.244

Review 9.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

Review 10.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.